Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-10731.47%
operating margin TTM
-11615.88%
revenue TTM
N/A
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -14.80 |
| peg ratio | -0.92 |
| price to book ratio | 7.82 |
| price to sales ratio | 1,661.62 |
| enterprise value multiple | -16.94 |
| price fair value | 7.82 |
profitability ratios | |
|---|---|
| gross profit margin | -77.06% |
| operating profit margin | -11615.88% |
| pretax profit margin | -10731.47% |
| net profit margin | -10731.47% |
| return on assets | -48.76% |
| return on equity | -47.13% |
| return on capital employed | -56.08% |
liquidity ratios | |
|---|---|
| current ratio | 16.31 |
| quick ratio | 16.31 |
| cash ratio | 11.25 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 211.59 |
| cash conversion cycle | -211.59 |
| receivables turnover | 0.00 |
| payables turnover | 1.73 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.02 |
| debt equity ratio | 0.02 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.02 |
| interest coverage | -1,128.40 |
| cash flow to debt ratio | -22.77 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.48 |
| cash per share | 0.99 |
| operating cash flow per share | -0.48 |
| free cash flow operating cash flow ratio | 0.99 |
| cash flow coverage ratios | -22.77 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -132.95 |
Frequently Asked Questions
When was the last time Regulus Therapeutics Inc. (NASDAQ:RGLS) reported earnings?
Regulus Therapeutics Inc. (RGLS) published its most recent earnings results on 08-05-2025.
What is Regulus Therapeutics Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Regulus Therapeutics Inc. (NASDAQ:RGLS)'s trailing twelve months ROE is -47.13%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Regulus Therapeutics Inc. (RGLS) currently has a ROA of -48.76%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did RGLS's net profit margin stand at?
RGLS reported a profit margin of -10731.47% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is RGLS's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 16.31 in the most recent quarter. The quick ratio stood at 16.31, with a Debt/Eq ratio of 0.02.